We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+22.53%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.83B
AUM Growth
+$508M
Cap. Flow
+$309M
Cap. Flow %
16.91%
Top 10 Hldgs %
53.61%
Holding
96
New
26
Increased
25
Reduced
14
Closed
27

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$52.8M
2
CELG
Celgene Corp
CELG
+$51.8M
3
BIIB icon
Biogen
BIIB
+$47.2M
4
PCRX icon
Pacira BioSciences
PCRX
+$41.8M
5
BURL icon
Burlington
BURL
+$32.2M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$73.6M
2
SGI
Somnigroup International
SGI
+$34.1M
3
SRCL
Stericycle Inc
SRCL
+$31.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.1M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 35.87%
2 Consumer Discretionary 11.8%
3 Consumer Staples 6.82%
4 Industrials 4.98%
5 Communication Services 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FL
76
DELISTED
Foot Locker
FL
– –
-212,000
Closed -$11.3M
INCY icon
77
Incyte
INCY
$24.2B
– –
-100,000
Closed -$6.36M
MRKR icon
78
Marker Therapeutics
MRKR
$18.8M
– –
-148,800
Closed -$8.26M
ORMP icon
79
Oramed Pharmaceuticals
ORMP
$167M
– –
-542,944
Closed -$1.63M
PALI icon
80
Palisade Bio
PALI
$330M
– –
-7
Closed -$185K
PULM icon
81
Pulmatrix
PULM
$6.35M
– –
-8,616
Closed -$414K
AIXC
82
AIxCrypto Holdings Inc
AIXC
$13.4M
– –
-4
Closed -$30K
REGN icon
83
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-70,000
Closed -$26.1M
SLDB icon
84
Solid Biosciences
SLDB
$794M
– –
-22,133
Closed -$8.9M
TENX icon
85
Tenax Therapeutics
TENX
$363M
– –
-53
Closed -$102K
TJX icon
86
TJX Companies
TJX
$174B
– –
-300,000
Closed -$13.4M
TOVX icon
87
Theriva Biologics
TOVX
$9.64M
– –
-2,228
Closed -$312K
UAA icon
88
Under Armour
UAA
$2.84B
– –
-30,000
Closed -$530K
TRAW icon
89
Traws Pharma
TRAW
$6.85M
– –
-78
Closed -$62K
SGI
90
Somnigroup International
SGI
$13.7B
– –
-3,296,000
Closed -$34.1M
SRCL
91
DELISTED
Stericycle Inc
SRCL
– –
-858,000
Closed -$31.5M
SEEL
92
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-40
Closed -$883K
FRTX
93
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-13,843
Closed -$5.14M
FLXN
94
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-400,000
Closed -$4.53M
ALXN
95
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-124,000
Closed -$12.1M
PGNX
96
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-5,700,000
Closed -$23.9M
1 2 3
4

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Armistice Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Armistice Capital held 96 positions worth $1.83B, up 38% from $1.32B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital deployed $309M of net new capital in Q1 2019, opening 26 new positions and adding to 25 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 425,000 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Clovis Oncology, Inc., an estimated $73.6M trimmed.

  • Armistice Capital's largest Q1 2019 buy was Madrigal Pharmaceuticals: 425,000 shares worth $53.2M.
  • Armistice Capital added most to Target in Q1 2019, an estimated $21.9M increase.
  • Armistice Capital's biggest Q1 2019 reduction was Clovis Oncology, Inc., cutting an estimated $73.6M.
  • Armistice Capital fully exited Somnigroup International in Q1 2019, selling an estimated $34.1M.
  • Armistice Capital's ten largest holdings make up 54% of its $1.83B portfolio in Q1 2019.
  • Armistice Capital opened 26 new positions and closed 27 in Q1 2019.
  • Armistice Capital's portfolio value rose 38% quarter-over-quarter to $1.83B.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.